

**TEXAS SOUTHERN UNIVERSITY  
BOARD OF REGENTS AGENDA**

**COMMITTEE:** Academic Affairs, Research and Student Life

**ITEM:** Request Approval to Purchase Research Equipment

**DATE PREVIOUSLY SUBMITTED:** N/A

**SUMMARY:**

The Administration requests approval to procure two advanced analytical research instruments. These acquisitions are critical to expanding the University's research infrastructure in drug discovery and development and will directly support doctoral-level education and training in pharmaceutical sciences.

**Instrument #1:** *TQ-8040 Triple Quadrupole Gas Chromatograph Mass Spectrometer with Electron Impact Ionization (GCMS/MS)* - Designed for high-sensitivity quantification of volatile and thermally stable drug compounds, supporting targeted pharmacological analysis.

**Instrument #2:** *Ultra High-Performance Liquid Chromatography (UHPLC) System with Photodiode Array Detector (PDA)* - Enables robust quantification of pharmaceuticals and their metabolites in complex biological matrices, essential for pharmacokinetic and biomarker studies.

The University awards contracts to a respondent whose proposal provides the best value to the State of Texas and Texas Southern University, as defined by Texas Government Code, § 2155.074.

SHIMADZU Scientific Instruments is recommended for this award. The purchase will be made via a cooperative purchasing agreement through E&I Cooperative Services, Contract Number: CNR-01405. SHIMADZU Scientific Instruments is not a HUB vendor and Form 1295 is submitted.

**SUPPORTING**

**DOCUMENTATION:** Quote (Under Separate Cover)

**FISCAL IMPACT:** Cost Not to Exceed: \$245,687  
FOAP: 3329 23540 7373 50 | BOA0001580

**ACTION REQUESTED:** Administration recommends approval of this item

**Legal Certification:** Based on available information to date, this action item and its implementation will not be in violation of any applicable federal, state, or local law, or regulation.



GENERAL COUNSEL

05/23/2025

DATE

**Fiscal Certification:** This fiscal note shown above details the true and actual positive or negative fiscal effect that implementation of this proposal will achieve.



John Pittman (May 27, 2025 14:07 CDT)

INTERIM CHIEF FINANCIAL OFFICER

05/27/2025

DATE



James Crawford (May 31, 2025 10:20 CDT)

PRESIDENT

05/31/2025

DATE